News | Nanologica

Nanologica to participate at Redeye R&D Tools Seminar Nov 10

3 November, 2020

November 10 at 10.15, Nanologica will participate at Redeye R&D Tools Seminar. The event can be live streamed on redeye.se. In this seminar, Redeye invites companies that provide tools & supplies for the biopharma industry and academia. An investment in this segment can offer exposure to strong underlying trends in the pharma industry, without necessarily taking binary bets. In recent years, some of the top performers within the life science sector belong to this segment,

Prof. Adam Feiler to Present at the Annual Surface and Materials Chemistry Symposium

19 October, 2020

The section for Surface and Materials Chemistry at the Swedish Chemical Society organizes The Annual Surface and Materials Chemistry Symposium, this year held on 21 – 22 October 2020. CTO of Nanologica, Prof. Adam Feiler, will during the symposium give a presentation on Development of porous silica particles for drug delivery. The symposium may be followed on Zoom after registration on https://asmcs.se/. Prof. Adam Feiler will present at 16.20 on Oct 21.

“En bättre värld är en bra affär” – artikel av Spotlight Stock Market

16 October, 2020

Stark tillväxt, tunga avtal i ryggen och en teknik med potential att förändra människors liv. Det är life science-företaget Nanologica. – “Vi har en produkt som kommer att slå världen med häpnad”, säger Andreas Bhagwani, vd på Nanologica. Läs hela artikeln här: https://spotlightstockmarket.com/sv/nanologica/

Vd Andreas Bhagwani kommenterar dagens pressmeddelande gällande uppdragsavtal med Vicore Pharma

26 June, 2020

Nanologicas nya styrelseledamot Tomas Kramar presenterar sig

29 May, 2020

Vd Andreas Bhagwani kommenterar Nanologicas årsstämma 2020

28 May, 2020

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Latest news

Categories

News archive